MIR. MedMira Inc.

MedMira reports additional independent performance evaluation results of REVEALCOVID-19™ Total Antibody Test

MedMira reports additional independent performance evaluation results of REVEALCOVID-19™ Total Antibody Test
EN
07/10/2020

Underlying

MIR.MedMira Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MedMira Inc.

 PRESS RELEASE
Free
MIR. MEDMIRA INC.

EQS-News: MedMira provides Progress Update

EQS-News: MedMira Inc. MedMira provides Progress Update 03.10.2022 / 13:04 CET/CEST The issuer is solely responsible for the content of this announcement. Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as MedMira’s Director of Scientific & Regulatory Affairs and provides an update on its regulatory progress in the U.S. market.U.S. Regulatory Update on COVID-19 ProductsThe recent announced recommendation by the U.S. FDA to IVD manufacturers to apply for the traditional regulatory path 510(k) approval outlines the continuous need for qua...

October 3, 2022 1 EN
 PRESS RELEASE
Free
MIR. MEDMIRA INC.

VYRA™ Product Line Update

VYRA™ Product Line Update HALIFAX, Nova Scotia, May 20, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRA™ product line. On the 10th of May 2022, Health Canada issued to all stakeholder further information about the current Interim Order No. 3. As a result, the regulators have clearly defined the pathway to achieve the Interim Order and with it provided the Company with the last requirement to complete its final application for their review. The final condition for MedMira is to complete an addit...

May 20, 2022 1 EN
 PRESS RELEASE
Free
MIR. MEDMIRA INC.

MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Anti...

MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test HALIFAX, Nova Scotia, May 12, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP). This approval allows the Company to further strengthen its product offering in all markets accepting the CE mark. By utilizing its unique RVF technology®, MedMira offers the only commercially available combined screening and confirmation te...

May 12, 2022 1 EN
 PRESS RELEASE
Free
MIR. MEDMIRA INC.

MedMira reports additional independent performance evaluation results ...

MedMira reports additional independent performance evaluation results of REVEALCOVID-19™ Total Antibody Test

October 7, 2020 1 EN
 PRESS RELEASE
Free
MIR. MEDMIRA INC.

MedMira gibt exklusive Vertriebspartnerschaft mit Webb Diagnostic Tech...

MedMira gibt exklusive Vertriebspartnerschaft mit Webb Diagnostic Technologies für Gesamtantikörpertest REVEALCOVID-19™ in den USA und erste Bestellung bekannt HALIFAX, Nova Scotia, May 28, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR) gibt bekannt, dass das Unternehmen für den Vertrieb des Gesamtantikörpertests REVEALCOVID-19™ eine exklusive Vertriebsvereinbarung mit Webb Diagnostic Technologies, Inc. (WebbDX) abgeschlossen hat.  Webb Diagnostic Technologies hat seine erste Bestellung im Wert von ca. 3,5 Millionen CAD aufgegeben. MedMira hat eine Anzahlung erhalten, um den ...

May 28, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch